Iparomlimab (Not yet branded)
Immunotherapy
Description
Iparomlimab is an experimental immunotherapy agent being evaluated in colorectal cancer, particularly in patients with BRAF V600E mutations and microsatellite stable (MSS) tumors. The drug appears to be tested in combination regimens including with FOLFIRI chemotherapy and with radiation therapy in conversion strategies for locally advanced disease. Clinical trials have focused on its potential role in metastatic colorectal cancer patients with specific molecular characteristics that typically have limited immunotherapy options.
Mechanism of Action
Iparomlimab appears to function as an immune checkpoint inhibitor, though the specific target pathway has not been fully characterized in available clinical data. The drug is designed to enhance the immune system's ability to recognize and attack cancer cells, particularly in the challenging MSS colorectal cancer population that traditionally shows poor response to standard immunotherapies.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Not yet branded |
| Category | Immunotherapy |
 Status | Experimental |
 EMA Status | Experimental |
 Spain Access | Not available |
| Administration | IV |
| Clinical Trials | 6 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.